Post Profile






Targeting estrogen receptor improves progression-free survival in advanced breast cancer

Fulvestrant significantly increases progression-free survival in women with hormone-receptor-positive advanced breast cancer, particularly those with less aggressive lower-volume disease, researchers report.
read more

share

Related Posts


Breast Conserving Therapy Shows Survival Benefit Compared to Mastectomy in Early-Stage Patients with Hormone Receptor Positive Disease

Health : Newswise Medical News

When factoring in what is now known about breast cancer biology and heterogeneity, breast conserving therapy (BCT) may offer a greater survival benefit over mastectomy to women with early stage, hormone-receptor positive disease, ac...

Higher doses of fulvestrant prolonged survival in patients with advanced breast cancer

Academics / General Science : ScienceDaily: Science Society

Increasing the dose of fulvestrant from 250 mg to 500 mg improved median overall survival in women with locally advanced or metastatic estrogen receptor-positive breast cancer, according to updated data.

Niraparib significantly improves outcome of ovarian cancer patients in landmark trial

Diseases & Conditions / Cancer : ScienceDaily: Cancer

The PARP inhibitor niraparib significantly improves the outcome of platinum-sensitive recurrent ovarian cancer, according to full data from a trial. The trial met its primary endpoint, with niraparib considerably prolonging progress...

Researchers discover new hormone receptors to target when treating breast cancer

Health : Medical News Today

About three-quarters of breast cancers, the most common cancer in women in the U.S., are estrogen hormone dependent. Patients with this type of breast cancer are initially treated with drugs that block estrogen, such as Tamoxifen. H...

Targeting estrogen receptor improves progression-free survival in advanced breast cancer

Health : EurekAlert: Health

(European Society for Medical Oncology) Fulvestrant significantly increases progression-free survival in women with hormone-receptor-positive advanced breast cancer, particularly those with less aggressive lower-volume disease, rese...

Comments


Copyright © 2016 Regator, LLC